Last reviewed · How we verify
ZR-202-CoV
At a glance
| Generic name | ZR-202-CoV |
|---|---|
| Sponsor | Shanghai Zerun Biotechnology Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults. (PHASE1, PHASE2)
- Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZR-202-CoV CI brief — competitive landscape report
- ZR-202-CoV updates RSS · CI watch RSS
- Shanghai Zerun Biotechnology Co.,Ltd portfolio CI